Helen P Pizzo1, Robert B Ettenger2, David W Gjertson3, Elaine F Reed3, Jennifer Zhang3, H Albin Gritsch4, Eileen W Tsai2. 1. Division of Pediatric Nephrology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. helen.pizzo@cshs.org. 2. Division of Pediatric Nephrology, Mattel Children's Hospital UCLA, Los Angeles, CA, USA. 3. UCLA Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA. 4. UCLA Department of Urology, Los Angeles, CA, USA.
Abstract
BACKGROUND: Immunosuppression medication nonadherence has been associated with donor-specific antibodies and treatment-refractory rejection. Drug-level monitoring is a practical direct marker for nonadherence, as variations indicate erratic ingestion of medication. We previously reported that high variability in tacrolimus trough levels determined by the percent coefficient of variation (CV %) and standard deviation (SD) were associated with biopsy-proven rejection. We hypothesized that the CV % and SD in patients on a sirolimus/low-dose tacrolimus regimen may associate with self-reported medication nonadherence, rejection and donor-specific antibodies. METHODS: In this pilot feasibility study, we studied 37 biopsies in 23 pediatric renal transplant patients on both sirolimus and tacrolimus immunosuppression; CV %, SD, de novo donor-specific antibodies, rejection, and self-reported adherence were examined. RESULTS: A cut-off sirolimus CV % of 25 maximized the percentage of biopsies correctly classified as rejection (32 of 37, or 86 %, p = 0.001). A cut-off tacrolimus CV % of 31 maximized the percentage of correctly classified biopsies (25 of 37, or 68 %, p = 0.09). Among patients with both high sirolimus and tacrolimus CV %, 67 % developed de novo donor-specific antibodies (p = 0.002) with a DQ predominance and 71 % reported nonadherence (p = 0.05). CONCLUSIONS: In pediatric renal transplantation, sirolimus and tacrolimus CV % is a potential tool for monitoring patients at risk for allograft rejection and donor-specific antibodies secondary to medication nonadherence.
BACKGROUND: Immunosuppression medication nonadherence has been associated with donor-specific antibodies and treatment-refractory rejection. Drug-level monitoring is a practical direct marker for nonadherence, as variations indicate erratic ingestion of medication. We previously reported that high variability in tacrolimus trough levels determined by the percent coefficient of variation (CV %) and standard deviation (SD) were associated with biopsy-proven rejection. We hypothesized that the CV % and SD in patients on a sirolimus/low-dose tacrolimus regimen may associate with self-reported medication nonadherence, rejection and donor-specific antibodies. METHODS: In this pilot feasibility study, we studied 37 biopsies in 23 pediatric renal transplant patients on both sirolimus and tacrolimus immunosuppression; CV %, SD, de novo donor-specific antibodies, rejection, and self-reported adherence were examined. RESULTS: A cut-off sirolimus CV % of 25 maximized the percentage of biopsies correctly classified as rejection (32 of 37, or 86 %, p = 0.001). A cut-off tacrolimus CV % of 31 maximized the percentage of correctly classified biopsies (25 of 37, or 68 %, p = 0.09). Among patients with both high sirolimus and tacrolimus CV %, 67 % developed de novo donor-specific antibodies (p = 0.002) with a DQ predominance and 71 % reported nonadherence (p = 0.05). CONCLUSIONS: In pediatric renal transplantation, sirolimus and tacrolimus CV % is a potential tool for monitoring patients at risk for allograft rejection and donor-specific antibodies secondary to medication nonadherence.
Entities:
Keywords:
Calcineurin inhibitor; Compliance; Drug levels; Immunosuppression; Mammalian target of rapamycin inhibitor
Authors: R Ganschow; L Pape; E Sturm; J Bauer; M Melter; P Gerner; B Höcker; T Ahlenstiel; M Kemper; F Brinkert; M M Sachse; B Tönshoff Journal: Pediatr Transplant Date: 2013-09-04
Authors: Eileen W Tsai; William D Wallace; David W Gjertson; Elaine F Reed; Robert B Ettenger Journal: Transplantation Date: 2010-10-27 Impact factor: 4.939
Authors: C Wiebe; D Pochinco; T D Blydt-Hansen; J Ho; P E Birk; M Karpinski; A Goldberg; L J Storsley; I W Gibson; D N Rush; P W Nickerson Journal: Am J Transplant Date: 2013-10-25 Impact factor: 8.086
Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086
Authors: Jill M Plevinsky; Ana M Gutierrez-Colina; Julia K Carmody; Kevin A Hommel; Lori E Crosby; Meghan E McGrady; Ahna L H Pai; Rachelle R Ramsey; Avani C Modi Journal: J Pediatr Psychol Date: 2020-04-01
Authors: N Ashwanikumar; Justin S Plaut; Barmak Mostofian; Siddharth Patel; Peter Kwak; Conroy Sun; Kerry McPhail; Daniel M Zuckerman; Sadik C Esener; Gaurav Sahay Journal: J Control Release Date: 2018-03-01 Impact factor: 9.776
Authors: Kim H Piburn; Vaka K Sigurjonsdottir; Olafur S Indridason; Lynn Maestretti; Mary Victoria Patton; Anne McGrath; Runolfur Palsson; Amy Gallo; Abanti Chaudhuri; Paul C Grimm Journal: Clin J Am Soc Nephrol Date: 2022-07-26 Impact factor: 10.614
Authors: Karmila Abu Bakar; Nor Asiah Mohamad; Zsolt Hodi; Tom McCulloch; Alun Williams; Martin Christian; Tim Key; Jon Jin Kim Journal: Pediatr Nephrol Date: 2019-09-13 Impact factor: 3.714
Authors: Jordana Herblum; Niki Dacouris; Michael Huang; Jeffrey Zaltzman; G V Ramesh Prasad; Michelle Nash; Lucy Chen Journal: Can J Kidney Health Dis Date: 2021-06-15